Tesamorelin 5 mg

DRAGON PHARMA TESAMORELIN 5 MG

Dragon Pharma Tesamorelin 5 mg stands as a pinnacle of precision in the world of performance-enhancing peptides. Unlike conventional growth hormone secretagogues, Tesamorelin is a selective growth hormone-releasing hormone (GHRH) analog specifically engineered to target and reduce stubborn visceral fat—the dangerous fat that accumulates around internal organs. For bodybuilders, fitness models, and athletes in the USA seeking a competitive edge, this pharmaceutical-grade peptide offers a powerful solution to sculpt a leaner, harder physique while potentially improving muscle quality and metabolic health. By stimulating a natural, pulsatile release of your body's own growth hormone, Dragon Pharma Tesamorelin promotes lipolysis (fat burning) with a notable preference for abdominal adipose tissue, without the bloating or significant water retention associated with direct GH use. Whether you're preparing for a contest, breaking through a fat loss plateau, or pursuing long-term body recomposition, this 5 mg vial represents a sophisticated, research-backed tool in your arsenal, delivered with the quality and reliability synonymous with the Dragon Pharma brand.

DRUG COMPOSITION

Each vial contains 5 mg of ultra-pure Tesamorelin acetate. Tesamorelin is a synthetic 44-amino acid peptide analog of Growth Hormone-Releasing Hormone (GHRH) with the sequence: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2. The "acetate" denotes the salt form, enhancing stability. The formulation is 100% active peptide with no fillers or preservatives in its lyophilized state.

PHARMACEUTICAL FORM

Sterile, white lyophilized (freeze-dried) powder presented in a 2 mL multi-dose glass vial, sealed with a bromobutyl rubber stopper and aluminum crimp cap. Requires reconstitution with Bacteriostatic Water prior to subcutaneous injection.

PHARMACEUTICAL GROUP AND ATC CODE

Tesamorelin is classified as a Growth Hormone-Releasing Hormone (GHRH) analog. Its primary therapeutic action aligns with drugs affecting the anterior pituitary gland. Its Anatomical Therapeutic Chemical (ATC) classification is H01AC05 - Somatropin agonists, under which specific GHRH analogs are categorized.

PHARMACOLOGICAL PROPERTIES

Tesamorelin is a potent and selective agonist of the growth hormone-releasing hormone receptor (GHRH-R) in the pituitary gland. Its mechanism is elegant and physiological:

• Natural GH Stimulation: It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering intracellular signaling that leads to the synthesis and pulsatile secretion of endogenous Growth Hormone (GH).
• IGF-1 Mediation: The released GH acts on the liver and other tissues to stimulate the production of Insulin-like Growth Factor 1 (IGF-1), which mediates many of the anabolic and metabolic effects.
• Targeted Lipolysis: The increased GH/IGF-1 axis activity markedly enhances lipolysis (the breakdown of fat), with a pronounced effect on visceral adipose tissue (VAT). Studies indicate it can reduce visceral fat by 15-20% over several months.
• Muscle Metabolism: It improves muscle quality and may support lean mass retention during caloric restriction by promoting protein synthesis and reducing protein breakdown, though its primary effect is not mass-building like anabolic steroids.
• Metabolic Benefits: Can improve lipid profiles and insulin sensitivity in certain populations, partly due to the reduction of metabolically harmful visceral fat.

Its key advantage is its selectivity; it mimics the body's natural GHRH, promoting a healthier, more natural GH pulse pattern compared to direct GH injection or non-selective secretagogues.

THERAPEUTICAL INDICATIONS

Within the research and athletic performance context, Dragon Pharma Tesamorelin 5 mg is indicated for:

• Visceral Fat Reduction: Primary use for targeted loss of deep abdominal (belly) fat that is resistant to diet and exercise, crucial for achieving a "shredded" look in bodybuilding.
• Body Recomposition: As an adjunct to disciplined nutrition and training to lower body fat percentage while preserving or enhancing muscle definition and hardness.
• Contest Preparation: A valuable tool in the final weeks before a competition to dial in conditioning without the subcutaneous water retention that can blur muscle lines.
• Metabolic Health Optimization: For athletes concerned with the long-term metabolic impact of performance-enhancing drug use, it can help manage visceral fat accumulation and improve related biomarkers.
• Anti-Aging & Recovery Support: Leveraging the restorative properties of increased GH (improved sleep, skin quality, connective tissue repair) in a more targeted manner than broader GH therapy.

DOSES AND METHOD OF ADMINISTRATION

• Reconstitution: Add 1-2 mL of Bacteriostatic Water to the 5 mg vial. Swirl gently until completely clear. Do not shake violently.
• Standard Research/Athletic Dosage: The clinically studied and most effective dose for fat loss is 2 mg (2000 mcg) administered via subcutaneous injection once daily. The Dragon Pharma 5 mg vial provides a 2.5-day supply at this dosage. Some protocols use 1 mg daily for milder effects.
• Cycle Length: Given its mechanism, Tesamorelin requires consistent, long-term use for significant fat loss. Cycles typically range from 12 to 26 weeks (3 to 6 months). Effects on visceral fat are progressive and cumulative.
• Administration: Best injected subcutaneously into the abdominal fat tissue at the same time each day, typically in the evening or before bed to align with the body's natural nocturnal GH surge. Rotate injection sites. Intramuscular injection is also effective but not necessary.

CYCLE/STACKING

Tesamorelin's fat-loss specificity makes it an ideal core component of cutting and recomposition stacks.

• With GHRPs for Synergy: Stack with a Growth Hormone-Releasing Peptide like GHRP-2 or Hexarelin 5 mg. This combination (a GHRH + a GHRP) creates a powerful synergistic release of GH, often greater than the sum of its parts, for enhanced fat loss and recovery.
• In a Cutting Stack: Combine with the potent beta-2 agonist Salbutamol for additional thermogenesis and with the thyroid hormone T3 (Cytomel) to elevate metabolic rate, creating a comprehensive fat-loss protocol.
• For Muscle Preservation During Cuts: Stack with a selective androgen receptor modulator (SARM) like LGD 4033 or MK 2866 to strongly preserve lean muscle mass while in a significant caloric deficit.
• With Insulin Sensitivity Agents: Pair with GW501516 (Cardarine) to further improve lipid metabolism, endurance, and insulin sensitivity, creating a potent metabolic enhancement stack.
• For Overall Wellness & Anti-Aging: Use alongside Sermorelin 5 mg (another GHRH) and MOTS-c 10mg for a broad-spectrum approach to cellular energy, metabolism, and rejuvenation.

POST CYCLE THERAPY (PCT)

Tesamorelin does not suppress the hypothalamic-pituitary-testicular axis (HPTA) like anabolic steroids. Therefore, it does not require traditional PCT with SERMs (e.g., Clomid, Nolvadex). However, because it acts on the pituitary to release GH, there is a theoretical concern about downregulation of natural GHRH receptors or somatotroph cell sensitivity with prolonged, high-dose use. A prudent approach is to cycle it (e.g., 12-16 weeks on, 4-8 weeks off) to allow pituitary sensitivity to reset. No drug-based PCT is needed, but the "off" period is the PCT for the GH axis.

SIDE EFFECTS

Tesamorelin is generally well-tolerated. Side effects are typically mild and related to increased GH activity. The most common include:

• Injection Site Reactions: Redness, itching, pain, or lumps.
• Transient Flushing/Warmth: Shortly after injection, some users report a brief flush.
• Joint Stiffness or Pain: Mild arthralgia due to fluid shifting into connective tissues.
• Muscle Pain: Occasional myalgia.
• Peripheral Edema: Mild swelling in hands or feet, significantly less than with direct GH use.
• Increased Appetite: A common effect of increased GH.

Notably, it does not typically cause the significant water retention, carpal tunnel syndrome, or insulin resistance seen with higher doses of exogenous GH. There is no hepatotoxicity or androgenic side effects.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to Tesamorelin or any component of the formulation. It should not be used by individuals with active malignancy (cancer), as GH can theoretically promote the growth of certain tumors. It is contraindicated in patients with pituitary tumors or acromegaly. Due to the lack of safety data, it is contraindicated during pregnancy and breastfeeding. Use with extreme caution in individuals with severe diabetes or a history of diabetic retinopathy.

OVERDOSE

There is no documented lethal dose. Acute overdose (significantly exceeding 2 mg daily) would likely amplify the side effects associated with GH excess: severe joint pain, significant edema, headaches, and intense hunger. Chronic overdose could potentially lead to acromegaly-like symptoms (abnormal bone growth) or worsen insulin resistance. Management involves immediate discontinuation and supportive/symptomatic care. The effects are reversible upon cessation.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

This product is for research purposes only. Not for human consumption as a drug. Individuals with pre-existing endocrine disorders, diabetes, or a history of cancer should consult a healthcare provider before considering use. Regular monitoring of fasting glucose and IGF-1 levels via blood work is advisable during long-term cycles to ensure safety. Use only sterile bacteriostatic water for reconstitution and practice strict aseptic injection technique to prevent infection. Do not share vials or needles. Keep out of reach of children.

INTERACTIONS WITH OTHER DRUGS

• Glucocorticoids (e.g., Cortisone, Prednisone): May antagonize the growth-promoting and lipolytic effects of Tesamorelin.
• Cyclosporine: Tesamorelin may increase the blood levels of cyclosporine, requiring monitoring.
• Other GH-Releasing Agents: Concomitant use with GHRPs (GHRP-2, GHRP-6, Hexarelin) or other GHRHs has a synergistic effect, which may increase both benefits and side effects.
• Insulin and Oral Hypoglycemics: GH can have anti-insulin effects. Diabetics using Tesamorelin may need to adjust their insulin or medication dosage under medical supervision.

PRESENTATION, PACKAGING

Dragon Pharma Tesamorelin 5 mg is presented in a professional, discreet box. Each box contains one 2 mL type I glass vial. The vial is stoppered, crimped, and features a flip-off plastic cap for tamper evidence. The label displays the Dragon Pharma logo, product name "Tesamorelin," strength "5 mg," batch number, expiry date, and storage instructions. Packaging is designed to protect the lyophilized powder from light and physical damage.

STORAGE

• Before Reconstitution: Store the sealed vial in a refrigerator at 2°C to 8°C (36°F to 46°F). For short periods (under 30 days), storage in a cool, dark place below 25°C (77°F) is acceptable. Avoid freezing the powder.
• After Reconstitution: The solution must be refrigerated immediately at 2°C to 8°C (36°F to 46°F). It remains stable and potent for up to 21 days when refrigerated. Discard if the solution becomes cloudy or discolored.

DELIVERY TO THE USA

We specialize in fast, reliable, and discreet shipping to all 50 states. Orders are processed within 24 hours on business days and shipped in plain, non-descript packaging with no external branding. We use trusted courier services with tracking provided upon dispatch. Delivery typically takes 3-7 business days within the continental USA. All payment gateways are secure and encrypted to protect your information.

LEGAL STATUS

Tesamorelin is a peptide that is not classified as a controlled substance under U.S. federal law (Controlled Substances Act). It is legally sold for laboratory research purposes. However, it is a prescription drug (Egrifta SV®) approved by the FDA for a specific medical condition (HIV-associated lipodystrophy). Its sale and purchase for human use outside of a valid prescription is illegal. This product is sold explicitly as a research chemical, and the buyer assumes all responsibility for compliance with local, state, and federal laws.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - Clinical study on Tesamorelin's efficacy in reducing visceral fat and improving metabolic parameters.
• Tesamorelin Injection: MedlinePlus Drug Information

PROFILE

• Chemical name: Tesamorelin Acetate
• Chemical formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Percentage of anabolic activity: Low indirect anabolic activity via IGF-1 (primarily muscle quality/preservation, not mass-building).
• Percentage of androgenic activity: 0% (Non-androgenic).
• Active half life: Approximately 26-38 minutes in serum, but its biological effect (GH pulse) drives longer-lasting IGF-1 production.
• Recommended dosage: 2 mg (2000 mcg) injected subcutaneously once daily.
• Acne: Rare, not a typical side effect.
• Bloating (water retention): Minimal to moderate; significantly less than exogenous GH.
• HBR (High Blood Pressure): No direct causal link; any effect would be secondary to fluid retention.
• Hepatic toxicity: None reported.
• Aromatization: Does not aromatize (does not convert to estrogen).